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An objective assessment of the variability
in number of drops per bottle of glaucoma
medication
Daniel B. Moore1*, Judy Beck1 and Richard J Kryscio2
Abstract
Background: The purpose of this study is to evaluate the number of eyedrops available per bottle of a variety of
commonly prescribed glaucoma medications.
Methods: Six bottles of each glaucoma medication were tested: three each in the vertical and horizontal
orientations. Bottles were housed in a customized force gauge apparatus designed to mimic ballpoint fingertip
contact with a bottle. At a standard rate, all drops were expressed from each bottle and counted with an
automated drop counter. Simultaneously, bottle volume was measured and drop size and number were also
estimated. The main outcome measures were: total number of drops, volume per bottle and drops per milliliter
(mL) of glaucoma medication.
Results: A total of 192 bottles from 32 bottle designs and manufacturers were tested. Twenty-two of the 32 bottle
designs had a significantly different mean number of drops in the vertical and horizontal positions, with 10 designs
have more drops dispensed in the horizontal orientation and 12 in the vertical orientation. Six of the 32 bottle designs
had a significantly different mean total bottle volume in the vertical and horizontal positions, with all designs having
greater volume in the vertical position. An adjusted ratio of mean number of drops/mean bottle volume demonstrated
a range from 20.9 drops/mL to 40.8 drops/mL.
Conclusions: There is significant variability in drops and volume available per bottle of glaucoma medication
depending on both the bottle position and manufacturer. These data point to the need for circumspection in
prescribing glaucoma medications and caution in evaluating therapeutic outcomes.
Keywords: Glaucoma, Pharmacology, Therapeutics, Eyedrop, Compliance, Bottle
Background
Although data demonstrate improved outcomes with
lowered intraocular pressure from appropriate pharma-
cotherapy [1, 2], many patients with glaucoma struggle
to adhere to their prescribed regimens. Several studies
suggest patients comply with 70% or fewer of their glau-
coma medications [3–5]. Many factors have been impli-
cated [6], but difficulty instilling drops has garnered
recent attention [7]. Proper eyedrop administration
requires eye-hand coordination and dexterity, linking
visual acuity with a steady hand and accurate
proprioception [8]. Not surprisingly, videotape evidence
demonstrated that glaucoma patient used an average
of 1.4–1.8 drops when trying to instill a single eye-
drop [9, 10]. A recent cross-sectional patient survey
revealed that 25% of patients reported problems with early
eyedrop bottle exhaustion and associated compliance with
therapy. One-third of patients reported the reason for
early bottle exhaustion was due to bottle related problems
such as “more than one drop comes out” or “size of drops
is too large”. The latter complaint is supported by litera-
ture that demonstrates the volume of an eyedrop in an
ophthalmic solution may vary from 25 to 70 μl [11]. Given
the normal tear film volume is 7 μl and only capable of
containing 30 μl without overflow, a significant portion of
an eyedrop is wasted [12]. These data suggest that a
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significant number of glaucoma patients run out of eye-
drops prior to a scheduled prescription refill and that bot-
tle related mechanics play a role [13].
Despite the importance of bottle design in proper use
of topical therapeutics, there exists no standardization of
manufacture in regards to drop instillation dynamics
[14], and the only dosing requirement is to accurately
label and package medication volume [15]. Being manu-
factured and sold on the basis of volume, eyedrops are
distinct from most other forms of pharmacotherapy,
which are prescribed with a discrete number of doses to
guide dispensing and refill rates. While the minimum
volume of medication consumers should anticipate per
container of medication is available, this does not neces-
sarily translate to number of applications, and without
regulation, leads to the possibility of inconsistency in the
number of drops of medicine available per bottle. Several
previous studies evaluating a smaller number of medica-
tions in a non-standardized fashion have found signifi-
cant variability in the number of drops between both
brands of medication and position of the bottle [16–18].
As such, the current study was designed to further
evaluate this possibility by objectively and systematically
measuring the number of eyedrops in each bottle of
many common glaucoma medications.
Methods
The number of eyedrops dispensed from various com-
mon glaucoma medications was measured. All medica-
tions were purchased at cost from the University of
Kentucky Research Pharmacy and represented available
regional brand and generic medications. A force gauge
apparatus consisting of a Mecmesin M500E Motorised
Tension and Compression Test Stand, Mecmesin 100 N
Advanced Force Gauge (Mecmesin Corporation, Sterling,
VA, USA) and custom grips and compressors were designed
and calibrated by JA King & Company (Whitsett, NC,
USA) (Fig. 1). The compressors were designed to mimic
ballpoint fingertip contact with a bottle. For each medi-
cation, the bottle was housed in the apparatus and
clamps were adjusted until the ballpoint compressors
were located at mid bottle length. For bottles with a
rectangular instead of round shape, the thinner dimen-
sions were chosen for compression, as this represents
the method most likely to be utilized by patients when
instilling drops. Starting at 0 kg-force (kgf ) and 0 mm
(mm) displacement, the gauge was advanced in 0.1 mm
increments until a drop of liquid fell from the bottle,
as observed subjectively and confirmed with an auto-
mated VCD-BTD drop counter (Vernier Software and
Technology, Beaverton, OR, USA) and LabQuest 2
display (Vernier Software and Technology, Beaverton, OR,
USA). At a rate of approximately one drop/s, 10 drops
were expressed, then the apparatus was retracted to 0 kgf.
This was repeated until all drops were exhausted from
the bottle.
Simultaneously, drop size and number was also esti-
mated using the densitometric method for volume deter-
mination [19]. In twenty drop increments, the total volume
of solution expressed was measured with a 0.0001 g
analytical balance (Ohaus Corporation, Parsippany, NJ,
USA). This was repeated until all drops were exhausted
from the bottle. A 200 uL pipette (Zhejiang Huawei
Scientific Instrument Co, LTD, Zhe Jiang, China) was
used to remove four 100-uL aliquots of each bottle.
The mean of the samples was divided by 0.1 mL to esti-
mate the volume of each drop and each bottle by dividing
the mass of each by the calculated density. For any bottles
with residual liquid in the container lid, this was removed
with the pipette and volume was measured separately.
Six bottles of each medication were tested. Three bot-
tles were tested in the vertical orientation with the bottle
Fig. 1 Force Gauge Apparatus. A force gauge apparatus consisting of a Mecmesin M500E Motorized Tension and Compression Stand, Mecmesin
100 N Advanced Force Gauge and custom grips and compressors were designed and calibrated by JA King & Company. a: The compressors were
designed to mimic ballpoint fingertip contact with a bottle tip. b: For each medication, the bottle was housed in the apparatus and clamps were
adjusted until the ballpoint compressors were located at mid bottle length. The L-shaped compression clamp was then adjusted until the force gauge
sensor was centered on the crosshairs of the clamp at a 90-degree angle
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Table 1 Description of Glaucoma Medications Tested
Medication Name Formulation Manufacturer
2.5 ml
Travatan travaprost 0.004% Alcon Laboratories, Inc. Fort Worth, TX 76134
Travaprost travaprost 0.004% Par Pharmaceutical Cos. Inc. Spring Valley, NY 10977
Xalatan latanoprost 0.005% Pharmacia&Upjohn Co, Division of Pfizer, Inc. NY, NY 10017
Latanoprost latanoprost 0.005% Akorn, Inc. Lake Forest, IL 60045
Lumigan bimatoprost 0.001% Allergan, Inc. Irvine, CA 92612
5 ml
Lumigan bimatoprost 0.001% Allergan, Inc. Irvine, CA 92612
Travaprost travaprost 0.004% Par Pharmaceutical Cos. Inc. Spring Valley, NY 10977
Travatan travaprost 0.004% Alcon Laboratories, Inc. Fort Worth, TX 76134
Alphagan P 0.1% brimonidine tartrate 0.1% Allergan, Inc. Irvine, CA 92612
Combigan brimonidine tartrate 0.2%,
timolol maleate 0.5%
Allergan, Inc. Irvine, CA 92612
Timolol Pacific timolol maleate 0.5% Pacific Pharma, Irvine CA, 92,612
Timolol Hi-Tech timolol maleate 0.5% Hi-Tech Pharmacal Co, Inc. Amityville, NY 11701
Timolol Sandoz timolol maleate 0.5% Alcon Laboratories, Inc. Fort Worth, TX 76134 for Sandoz Inc.
Pricenton, NJ 08540
Betimol timolol maleate 0.5% Akorn, Inc. Lake Forest, IL 60045 for Oak Pharmaceuticals, Inc.
Timoptic XE timolol maleate 0.5% Merck Sharp & Dohme-Chibret 63,963 Clermont-Ferrand Cedex
9, France; Distributed by Valeant Ophthalmics, a division of
Valeant Pharmaceuticals North America LLC,
Bridgewater, NJ 08807
Timoptic timolol maleate 0.5% Merck Sharp & Dohme-Chibret 63,963 Clermont-Ferrand Cedex
9, France; Distributed by Valeant Ophthalmics,
a division of Valeant Pharmaceuticals
North America LLC, Bridgewater, NJ 08807
Istalol timolol maleate 0.5% Bausch&Lomb Incorporated Tampa, FL 33637 under License
from Senju Pharmaceutical Co, Ltd. Osaka, Japan 541–0046
7.5 ml
Lumigan bimatoprost 0.001% Allergan, Inc. Irvine, CA 92612
8 ml
Simbrinza brinzolamide 1%, brimonidine
tartrate 0.2%
Alcon Laboratories, INC 6201 South Freeway, Fort Worth, TX 76134
10 ml
Cosopt dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml
Akorn, Inc. Lake Forest, IL 60045
Dorz/Tim Hi-Tech dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml
Hi-Tech Pharmacal Co, Inc. Amityville, NY 11701
Dorz/Tim Bausch dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml
Bausch & Lomb Incorporated Tampl, FL 33637
Dorz/Tim Sandoz dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml
Alcon Laboratories Inc. Fort Worth Tx 76,134 for Sandoz Inc.
Princeton, NJ 08540
Trusopt dorzolamide HCL 2% Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co, Inc.
Whitehouse Station, NJ 08889
Dorz Hi Tech dorzolamide HCL 2% Hi-Tech Pharmacal Co, Inc. Amityville, NY 11701
Dorz Bausch dorzolamide HCL 2% Bausch & Lomb Incorporated Tampa, FL 33637
Dorz Teva dorzolamide HCL 2% Teva Pharmaceutical Ind, Ltd. Jerusalem, 91,010, Israel for Teva
Pharmaceuticals USA Sellersville, PA 18960
Dorz Sandoz dorzolamide HCL 2% Alcon Laboratires, Inc. Fort Worth, TX 76134 for Sandoz Inc.
Princeton, NJ 08540
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tip at 180 degrees and three bottles were tested in the
near horizontal orientation with the bottle tip at 30
degrees. The vertical and horizontal orientations were
the starting position for the bottle tip during each meas-
urement, as compression of the bottle variably and
slightly changed the tip position.
Statistical analysis
Mean response was compared by constructing an ana-
lysis of variance for a two way layout with factors:
position (horizontal versus vertical) and bottle (all com-
binations of medication name and formulation). A highly
significant interaction between position and bottle was
obtained (p < 0.0001). Post hoc comparison of means
was done by comparing means between positions for
each bottle by using two sample t-tests. To compare dif-
ferent bottle designs in the same orientation, Fisher’s
least significant differences allowance was computed.
Statistical significance was determined at the 0.01 level
to minimize the Type I error rate.
Results
A total of 192 bottles from 32 bottle designs and manu-
facturers of medication were tested (Table 1). Further
reference to medications will include brand name,
manufacturer if more than one generic and bottle
volume for identification. Fifteen formulations came
from the same lot, sixteen came from a combination of
two different lots and one came from a combination of
three different lots. When comparing the mean value of
variance between formulations from the same or differ-
ent lots, there was no statistical difference (p = 0.62).
Comparing mean number of drops per bottle using
observed measurements versus the densitometric method
to calculate number of drops in the bottle, there was no
difference in the vertical (p = 0.35, paired t-test), but
a significant difference between measurements in the
horizontal (p = 0.02, paired t-test) position. Observed
measurements via the automated drop counter were
used for subsequent analysis.
The mean number and standard deviation of drops per
bottle in the horizontal, vertical and summative positions
of all formulations are provided in Table 2. For
2.5 mL bottles, the mean number of drops ranged
from 75.3–101.7 and 72–102.3 in the vertical and
horizontal orientations, respectively. For 5 mL bottles, the
range was 111–209.3 and 115–189 drops in the vertical
and horizontal orientations, respectively. For 10 mL bot-
tles, the range was 193.7–313.3 and 234–323.7 drops in
the vertical and horizontal orientations, respectively.
Twenty-two of the 32 bottle designs had a significantly
different mean number of drops in the vertical and hori-
zontal positions, with 10 designs have more drops dis-
pensed in the horizontal orientation and 12 in the vertical.
The mean bottle and drop volume are also listed in
Table 2. Bottle volumes were measured with and without
accounting for residual volume in the cap of the con-
tainer, with less than a 2.2% difference of the overall
mean in 90% of the bottles. Presented bottle volume
measurements include the cap volume. For 2.5 mL bot-
tles, the range was 2.37–2.69 mL and 2.38–2.70 mL in
the vertical and horizontal orientations, respectively. For
5 mL bottles, the range was 4.72–5.93 mL and
4.67–5.66 mL in the vertical and horizontal orientations,
respectively. For 10 mL bottles, the range was
8.93–10.2 mL and 8.38–9.79 mL in the vertical and hori-
zontal orientations, respectively. Six of the 32 bottle
designs had a significantly different mean total bottle
volume in the vertical and horizontal positions, with all
designs having greater volume in the vertical position.
There were no significant differences between the horizon-
tal and vertical measured drop volume for any designs.
Given the multiple different comparisons possible
between bottle type, size and volume, an adjusted ratio
of mean number of drops/mean bottle volume was
created (Table 2), with a range from 20.9 drops/mL to
40.8 drops/mL among the bottle designs and positions.
Nineteen formulations had a significantly different ratio
between the horizontal and vertical positions (p < 0.01).
For comparing means between two bottle designs in the
same orientation, any two means that differ by a value of
5.27 or greater are significantly different (p < 0.01).
Discussion
The results of this study suggest there is significant vari-
ability in the number of drops and volume per bottle of
glaucoma medications, both in terms of which bottle
design and manufacturer is utilized and the position the
bottle is held when squeezed. For example, if a represen-
tative patient from this region is prescribed a 5 mL
Table 1 Description of Glaucoma Medications Tested (Continued)
Azopt brinzolamide 1% Alcon Laboratories, Inc. Fort Worth, TX 76134
Combigan brimonidine tartrate 0.2%, timolol maleate 0.5% Allergan, Inc. Irvine, CA 92612
Alphagan P 0.15% brimonidine tartrate 0.15% Allergan, Inc. Irvine, CA 92612
Alphagan P 0.1% brimonidine tartrate 0.1% Allergan, Inc. Irvine, CA 92612
The medication name and volume used in the study, the formulation and manufacturer are listed
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Table 2 Mean Number of Drops, Volume and Drop/Volume Ratio per Glaucoma Medication Tested
Drop Mean # Drops Mean Bottle Volume Mean Drop
Volume
Mean Drops/mL
vert horz p value vert horz p value vert horz vert horz p value
2.5 ml
Travatan 76.3 ± 4.2 102.3 ± 1.5 <0.01 2.57 ± 0.07 2.53 ± 0.04 0.032 0.025 29.66 ± 1.35 40.4 ± 1.07 0.0004
Travaprost 75.3 ± 5.1 72 ± 1 2.46 ± 0.04 2.36 ± 0.07 0.032 0.032 30.6 ± 2.51 30.47 ± 1.14 0.9445
Xalatan 101.3 ± 0.6 83.3 ± 3.1 2.69 ± 0.05 2.70 ± 0.05 0.027 0.032 37.68 ± 0.73 30.90 ± 0.60 0.0002
Latanoprost 86.7 ± 9.3 76.7 ± 5.0 2.37 ± 0.26 2.42 ± 0.13 0.027 0.032 36.59 ± 0.98 31.63 ± 0.76 0.0023
Lumigan 101.7 ± 2.3 81.7 ± 4.0 <0.01 2.50 ± 0.05 2.38 ± 0.08 0.024 0.029 40.61 ± 0.18 34.25 ± 0.63 <0.0001
overall mean 88.3 83.2 2.52 2.48 0.029 0.03
overall median 91 81 2.53 2.46 0.027 0.031
overall ST DEV 12.7 11.08 0.15 0.15 0.004 0.003
5 ml
Lumigan 195.6 ± 4.2 155 ± 1 <0.01 4.97 ± 0.06 4.73 ± 0.06 0.025 0.03 39.4 ± 0.69 32.75 ± 0.22 <0.001
Travaprost 150.3 ± 6.5 139.7 ± 13.7 4.91 ± 0.02 4.78 ± 0.24 0.032 0.035 30.62 ± 1.42 29.15 ± 1.50 0.2859
Travatan 146.3 ± 0.6 189 ± 1 <0.01 4.8 ± 0.04 4.78 ± 0.07 0.033 0.026 30.49 ± 0.82 29.66 ± 1.35 0.0004
Alphagan P 111 ± 1 117 ± 2.6 4.89 ± 0.05 4.72 ± 0.18 0.044 0.04 22.7 ± 0.16 24.82 ± 0.78 0.0102
Combigan 148 ± 2 161.3 ± 3.8 5.02 ± 0.16 4.67 ± 0.07 0.01 0.033 0.029 25.26 ± 1.53 34.57 ± 0.50 0.0003
Timolol Pacific 123 ± 1 147.7 ± 9.6 <0.01 4.88 ± 0.04 4.69 ± 0.10 0.04 0.031 25.21 ± 0.09 25.21 ± 0.09 0.0206
Timolol Hi-Tech 126.7 ± 6.7 149.3 ± 4.0 <0.01 5.09 ± 0.15 5.04 ± 0.13 0.041 0.034 24.89 ± 0.56 29.61 ± 0.633 0.0006
Timolol Sandoz 161.3 ± 3.5 156.3 ± 2.5 4.89 ± 0.04 4.84 ± 0.08 0.03 0.031 33.02 ± 0.92 32.28 ± 0.21 0.2459
Betimol 165.3 ± 0.6 160.7 ± 1.2 5.17 ± 0.035 5.08 ± 0.06 0.031 0.031 32.00 ± 0.14 31.63 ± 0.56 0.3282
Timoptic XE 130.7 ± 7.5 115 ± 9.8 0.004 5.53 ± 0.24 4.9 ± 0.24 0.042 0.043 23.71 ± 2.41 23.45 ± 1.16 0.8734
Timoptic 209.3 ± 5.7 155.3 ± 7.1 <0.01 5.93 ± 0.03 5.66 ± 0.03 0.0003 0.089 0.036 35.28 ± 0.82 27.6 ± 1.21 0.0008
Istalol 154.6 ± 2.1 165.6 ± 2.5 4.72 ± 0.03 4.74 ± 0.09 0.03 0.029 32.77 ± 0.22 34.95 ± 0.32 0.0006
overall mean 151.9 151 5.06 4.89 0.039 0.033
overall median 149 155.2 4.93 4.78 0.033 0.031
overall ST DEV 28.2 20.26 0.34 0.28 0.03 0.005
7.5 ml
Lumigan 294 ± 2.6 236 ± 2 <0.01 7.21 ± 0.06 7.18 ± 0.03 0.024 0.03 40.76 ± 0.56 32.85 ± 0.18 <0.001
8 ml
Simbrinza 180.7 ± 3.1 219.7 ± 6.7 <0.01 7.51 ± 0.03 6.74 ± 0.12 0.0004 0.167 0.031 24.07 ± 0.47 32.58 ± 1.22 0.0003
10 ml
Cosopt 301.7 ± 39.6 242 ± 12.5 <0.01 10.2 ± 0.17 9.58 ± 0.18 0.01 0.033 0.039 29.56 ± 3.66 25.26 ± 1.53 0.1341
Dorz/Tim Hi-Tech 303 ± 1 251.7 ± 10.0 <0.01 9.23 ± 0.34 9.19 ± 0.26 0.031 0.038 32.85 ± 1.22 27.39 ± 0.39 0.0018
Dorz/Tim Bausch 313.3 ± 1.5 293.7 ± 1.5 <0.01 9.22 ± 0.23 8.91 ± 0.21 0.03 0.031 34.01 ± 0.92 32.96 ± 0.65 0.1804
Dorz/Tim Sandoz 315 ± 4.6 271.3 ± 5.8 <0.01 8.93 ± 0.15 8.39 ± 0.29 0.115 0.031 35.27 ± 1.09 32.37 ± 1.03 0.0288
Trusopt 313.3 ± 20.0 236 ± 5.6 <0.01 10.18 ± 0.20 9.60 ± 0.33 0.221 0.051 30.77 ± 1.86 24.59 ± 0.94 0.0068
Dorz Hi Tech 292.7 ± 10.3 261.7 ± 12.9 <0.01 9.54 ± 0.19 9.13 ± 0.29 0.033 0.035 20.92 ± 17.91 28.70 ± 2.21 0.5313
Dorz Bausch 289.7 ± 4.2 289 ± 4.6 9.18 ± 0.26 8.78 ± 0.15 0.032 0.03 31.55 ± 0.61 32.91 ± 0.06 0.0594
Dorz Teva 282 ± 11.5 260 ± 1 <0.01 9.31 ± 0.58 8.69 ± 0.12 0.033 0.034 30.33 ± 0.79 29.91 ± 0.31 0.4423
Dorz Sandoz 193.7 ± 3.79 253.7 ± 15.3 <0.01 9.19 ± 0.12 8.38 ± 0.08 0.0006 0.332 0.034 21.06 ± 0.16 30.26 ± 1.94 0.014
Azopt 254.3 ± 2.1 322 ± 8.9 <0.01 9.42 ± 0.08 8.59 ± 0.04 <0.0001 0.037 0.027 27.01 ± 0.38 37.5 ± 1.08 <0.001
Combigan 270.3 ± 28.4 323.7 ± 17.8 <0.01 9.86 ± 0.21 9.79 ± 0.07 0.034 0.03 27.4 ± 2.50 33.07 ± 1.64 0.0303
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bottle of timolol 0.5%, there are 5 different generic and
brand bottle designs that may be dispensed. The patient
could anticipate a range of 123–209 and 147–166 mean
drops per bottle in the horizontal and vertical positions,
respectively. If instilled twice daily, this would suggest a
difference between 25.5 to 43 days of available medica-
tion depending on the manufacturer and bottle position.
This study is the first to our knowledge to present an
objective, automated and reproducible method to meas-
ure the number of drops available per bottle of medica-
tion. Further, we measured countable drops instead of
calculating the number of drops based on volume, which
was shown to be inaccurate. Several previous studies
have evaluated small samples of bottle formulations with
similar, variable results. A 1994 study of patients blinded
to either use of a 5 mL bottle of timolol maleate versus
levobunolol found a 21% greater length of use of timolol
(37 versus 29 days) [16]. Another study evaluated 45 ver-
sus 90 degree administration of artificial tear bottles and
found a significantly greater number of drops per bottle
using densitometric analysis and smaller drop volume
for 4 out of 5 formulations at 45 compared to 90 degrees.
The authors suggest administration at 45 degrees would
result in up to $1.93 savings per bottle compared to 90
degrees [17]. A study evaluating 2.5 ml bottles of prosta-
glandin analogues held vertically, at 45 degrees and hori-
zontally found that vertical instillation resulted in more
drops per bottle for bimatoprost and latanoprost, while 45
degrees was most efficient for travaprost. Assuming 1 year
of bilateral therapy at 2006 costs, the authors determined
use of the most efficient instillation method would result
in yearly savings of $109–192 [18]. Lastly, a recent study
found significant variability in the number of eyedrops per
bottle of four regionally available formulations of latano-
prost when measured by manually counting the number
of drops expressed by hand, ranging from 77.6 to 88.7
drops per bottle. The authors estimated a similarly signifi-
cant difference in estimated annual cost, ranging from
$184 to $1198 per formulation [20].
Currently, there exist no federal guidelines to regulate
bottle design or amount of drops available per volume of
medication [14, 15]. It has been suggested that pharmacists
often use a rough guideline of 0.05 mL per eyedrop or 20
drops per mL (written personal communication, Division
of Drug Information, FDA, March 27, 2015). With that in
mind, there are significantly more eyedrops per bottle in
this analysis than recommended, ranging from 10.4% to
45.8% more mean drops per bottle tested. This may indi-
cate that manufacturers “overfill” the bottles to allow for a
margin of error during dispensing. If true, this serves an
important purpose, since it is known that many patients
require more than one eyedrop per application [9, 10].
However, this data suggests another problem has been cre-
ated by this practice: significant variability in the number
of doses per bottle.
Aside from bottle volume, an additional factor influ-
ence the number of drops available per bottle is drop
size. We found significant variability in the estimated
drop size of studied formulations, ranging from 0.024 to
0.221 mL. The size of drop dispensed from a bottle
depends on three basic elements: the design of the drop-
per bottle and tip, properties of the contained solution
and the position of the bottle. The surface area around
the bottle tip and surface tension of the solution are
both manufacturer controlled factors that influence drop
size. Patient manipulations such as the angle and rate
drops are produced are less predictable [11]. Further, the
results of the current study and others suggest the most
economical bottle position varies from one design to the
next [17–19]. A final potential determinant of drop size
is the force required to squeeze the bottle, which unfor-
tunately is significantly variable in both the experimental
and clinical setting [21, 22]. With all of these influences,
it may be difficult to design an ideal bottle for instilla-
tion. One expert suggestion has been to utilize a dropper
tip with a smaller outer orifice diameter that provides
consistent surface area for a smaller-volume drop to fall
[11].
This study has several limitations. The experimental
design was novel, and although measurements were
automated, they have not been independently verified.
Because the study was conducted in an objective and
reproducible manner, it may not accurately reflect many
of the patient related factors in dosing; it is likely that
Table 2 Mean Number of Drops, Volume and Drop/Volume Ratio per Glaucoma Medication Tested (Continued)
Alphagan 0.15% 212.7 ± 3.1 234 ± 3.6 <0.01 9.78 ± 0 9.53 ± 0.09 0.046 0.041 21.75 ± 0.31 24.56 ± 0.16 0.0002
Alphagan 0.1% 216 ± 4 283.3 ± 5.5 <0.01 9.93 ± 0.19 9.61 ± 0.07 0.046 0.037 21.75 ± 0.11 24.80 ± 0.41 0.0002
overall mean 273.7 267.5 9.54 9.09 0.079 0.034
overall median 290 261 9.51 9.02 0.034 0.033
overall ST DEV 42.69 31.07 0.45 0.51 0.119 0.005
The mean number of drops, bottle volume, drop volume and ratio of mean number of drops per bottle volume of three bottles tested for each medication in the
vertical and horizontal positions. Medications are grouped by volume and an overall mean, median and standard deviation for all medications of similar volumes
are provided. A p-value for medications with a significant difference in mean drop number between the horizontal and vertical position is listed, with significance
determined at p = 0.01. A ratio of mean number of drops/mean bottle volume is listed, and any two means that differ by a value of 5.27 or greater are
significantly different (p < 0.01). Volume measurements are in milliliters (mL). A bold value indicates a p value of statistical significance
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our patients experience even greater variability in the
number of drops available per bottle. Only two bottle
positions were tested and most ophthalmic containers
are not intended to be delivered in a strictly horizontal
position. While 192 bottles from 32 bottle designs were
tested, they still represent a small sampling of all avail-
able brand and generic ophthalmic medications.
Conclusion
In summary, this study demonstrates the significant vari-
ability in drops and volume available per bottle of glau-
coma medication depending on both the bottle position
and manufacturer. This unregulated practice leaves pre-
scribing physicians and pharmacists unable to accurately
predict the quantity of medication to dispense. This may
lead to patients running out of medication early or being
left with excess and associated costs. The variability from
one refill to the next could be a contributor to limited
compliance. The experimental design in this study indi-
cates an objective, reproducible method to determine drop
number uniformly across different bottles and designs. It
should compel further evaluation and consideration of
standardization in the industry.
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